In 2023, veterinary drugs on the Russian retail market (e-com included) went up in price 26.6% from 2022. The highest price growth rates were seen in early 2023 (Fig. 1); as a result of the devaluation of the ruble and the subsequent correction of prices for imported goods on the Russian market, inflation surged in June–August 2023. By the end of the year, the prices had stabilized, dropping to a year-low. January and February 2024, however, saw an upward trend (26.4% and 28.6%, respectively), which peaked in March 2024 with 44.9%, going back to last year’s index. In January–March 2024, the price index was 34.7%.

In Q1 2024, 8.7 billion rubles worth of veterinary drugs were sold on the Russian veterinary retail market (retail prices, VAT included), up 13.5% from Q1 2023. In physical terms, 57.7 million minimum dosage units (MDU) were sold, up 11.8% from Q1 2023. The offline channel, as well as the online segment, saw positive growth rates.

In Q1 2024, 1.8 billion rubles’ worth of nebulizers were sold on the Russian retail market (retail prices, VAT included), up 38% from Q1 2023. In physical terms, 752,000 devices were sold, up 51% from the same period in 2023. In 2023, however, 4.9 billion rubles’ worth of nebulizers were sold, up by only 0.5% in rubles and by 10% in units from 2022. The product range has been changing, which affects the average price—it was 2,390 rubles in Q1 2024 against 2,610 in Q1 2023. As well as for almost any other category of medical devices, the price index for nebulizers was negative. In Q1 2024, the prices began to rise, with an inflation rate of 3.3%.

In 2023, around 6.0 million of blood pressure monitors worth 11.9 billion rubles (retail prices, VAT included) were sold on the offline and online retail markets in Russia. The sales went up 29% in physical and up 10% in monetary terms. At the same time, the average price dropped—it was 1,970 rubles in 2023 against 2,310 in 2022. While the prices for this category of medical equipment in 2023 dropped 5% from 2022, the inflation rate in Q1 2024 was 2.7% against Q1 2023.